About: An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
Creator	Gale, Michael Feldmann, Heinz Veesler, David Walls, Alexandra Fuller, James Carter, Darrick Reed, Steven Hemann, Emily Fuller, Deborah Hawman, David Archer, Jacob Berglund, Peter Draves, Kevin Duthie, Malcolm Erasmus, Jesse Guerriero, Kathryn Khandhar, Amit Leventhal, Shanna Lewis, Thomas Murapa, Patience O'connor, Megan Randall, Samantha
Source	Medline; PMC
abstract	The COVID-19 pandemic, caused by infection with the SARS-CoV-2 coronavirus, is having a deleterious impact on health services and the global economy, highlighting the urgent need for an effective vaccine. Such a vaccine would need to rapidly confer protection after one or two doses and would need to be manufactured using components suitable for scale-up. Here, we developed an alphavirus-derived replicon RNA vaccine candidate, repRNA-CoV2S, encoding the SARS-CoV-2 spike (S) protein. The RNA replicons were formulated with Lipid InOrganic Nanoparticles (LION) that were designed to enhance vaccine stability, delivery, and immunogenicity. We show that a single intramuscular injection of the LION/repRNA-CoV2S vaccine in mice elicited robust production of anti-SARS-CoV-2 S protein IgG antibody isotypes indicative of a Type 1 T helper cell response. A prime/boost regimen induced potent T cell responses in mice including antigen-specific responses in lung and spleen. Prime-only immunization of aged (17-month old) mice induced smaller immune responses compared to young mice, but this difference was abrogated by booster immunization. Importantly, in nonhuman primates, prime-only immunization in one intramuscular injection site or prime/boost immunizations in 5 intramuscular injection sites elicited modest T cell responses and robust antibody responses. The antibody responses persisted for at least 70 days and neutralized SARS-CoV-2 at titers comparable to those in human serum samples collected from individuals convalescing from COVID-19. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection against SARS-CoV-2 infection.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1126/scitranslmed.abc9396
bibo:pmid	32690628
has license	cc-by
sha1sum (hex)	fc81b13024b83488ca628123c21170ac836fb5fe
schema:url	https://doi.org/10.1126/scitranslmed.abc9396
resource representing a document's title	An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates
has PubMed Central identifier	PMC7402629
has PubMed identifier	32690628
schema:publication	Sci Transl Med
resource representing a document's body	covid:fc81b13024b83488ca628123c21170ac836fb5fe#body_text
is schema:about of	named entity 'titers' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'mice' named entity 'boost' named entity 'response' named entity 'enhance' named entity 'CAUSED BY' named entity 'IMMUNE RESPONSES' named entity 'MICE' named entity 'ENCODING' named entity 'SCALE' named entity 'COVID-19' named entity 'INJECTION SITE' named entity 'IMMUNIZATION' named entity '28S' named entity 'HIGHLIGHTING' named entity 'PROPHYLACTIC' named entity 'MANUFACTURED' named entity 'REGIMEN' named entity 'IMPACT' named entity 'DELIVERY' named entity 'DIFFERENCE' named entity 'spleen' named entity 'scale-up' named entity 'encoding' named entity 'human' named entity 'replicon' named entity 'RNA vaccine' named entity 'manufactured' named entity 'site' named entity 'infection' named entity 'global economy' named entity 'Lipid' named entity 'COVID' named entity 'spike (S) protein' named entity 'young mice' named entity 'intramuscular injection' named entity 'vaccine' named entity 'mice' named entity 'SARS-CoV-2' named entity 'mice' named entity 'immunization' named entity 'isotypes' named entity 'SARS-CoV-2' named entity 'spleen' named entity 'immunizations' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'immunizations' named entity 'antibody' named entity 'peptide' named entity 'Lipid' named entity 'Venezuelan equine encephalitis virus' named entity 'rhesus macaques' named entity 'clone' named entity 'clinical trials' named entity 'pathology' named entity 'DNA vaccines' named entity 'anionic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software